Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00714116 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
A Phase 1 study of Lupus Erythematosus, Systemic, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT00714116 is a Phase 1 study of Lupus Erythematosus, Systemic that has completed, run by Pfizer. The registered enrollment target is 30 participants, below the 202-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00714116, a Phase 1 study of Lupus Erythematosus, Systemic, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
Conditions Studied
Interventions
- DRUG SBI-087
Study Locations (6)
Florida
- Arthritis & Rheumatology Care Center - South Miami
- Miami Research Associates - South Miami
- MRA Clinical Research - South Miami
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Texas
- Metroplex Clinical Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00714116
The ClinicalTrials.gov registry entry for NCT00714116 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (85% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 1 intervention - of which SBI-087 is the first listed.
NCT00714116 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Florida, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00714116 about?
NCT00714116 is a clinical study titled "Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus". The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT00714116?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-03. Estimated completion is 2012-09.
What conditions does trial NCT00714116 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT00714116?
The interventions under investigation include: SBI-087 (DRUG).
Who is sponsoring clinical trial NCT00714116?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00714116 being conducted?
This trial has 6 study locations across Florida, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Anti-CD20 in Systemic Lupus Erythematosus
COMPLETED · Phase 1
-
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
COMPLETED · Phase 1
-
Phase Ib Study of SC Milatuzumab in SLE
COMPLETED · Phase 1
-
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.